Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00933088 · ClinicalTrials.gov registry record

Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer

A clinical trial, sponsored by NYU Langone Health.

Terminated
Registry status
43
Enrollment target

NCT00933088: Clinical Trial study, sponsored by NYU Langone Health.

NCT00933088 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00933088 was terminated before completion, sponsored by NYU Langone Health.

TERMINATED
Registry status
43 participants
Enrollment target

Study Summary

The aims of this study are to determine the differential coping strategies used by adolescent daughters whose mothers have breast cancer, and how this relates to the stress responses they exhibit.

Interventions

  • OTHER questionnaires

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2008-06
Est. Completion 2009-10
NYU Langone Health

1,164 total trials

Why NCT00933088 stopped before completion

NCT00933088 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which questionnaires is the first listed.

NCT00933088 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00933088 about?

NCT00933088 is a clinical study titled "Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer". The aims of this study are to determine the differential coping strategies used by adolescent daughters whose mothers have breast cancer, and how this relates to the stress responses they exhibit.

What is the current status of trial NCT00933088?

This trial is currently terminated. The enrollment target is 43 participants. The study started on 2008-06. Estimated completion is 2009-10.

What interventions are being tested in trial NCT00933088?

The interventions under investigation include: questionnaires (OTHER).

Who is sponsoring clinical trial NCT00933088?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00933088, the US trial registry maintained by the National Library of Medicine. NCT00933088 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.